重症患者接受体外生命支持技术时抗多重耐药革兰阴性杆菌β-内酰胺类抗生素给药策略的全国调查与共识文件:DOSEBL研究方案
该研究方案针对接受体外生命支持技术(连续性肾脏替代治疗、常规间歇性血液透析、体外膜肺氧合)的重症患者,这些技术可引入额外的药代动力学改变,可能导致抗生素暴露不足。项目分两阶段:全国调查和共识文件开发,共识按ACCORD指南进行,包括多学科专家组、前瞻性注册、证据合成和改良Delphi轮次。纳入抗菌药物为美罗培南、头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、头孢地尔、美罗培南/法硼巴坦、亚胺培南/瑞来巴坦和氨曲南。研究旨在基于现有证据制定标准化给药和监测策略的共识文件。
要点
- 研究聚焦接受体外生命支持技术(连续性肾脏替代治疗、常规间歇性血液透析、体外膜肺氧合)的重症患者中MDR-GNB感染的β-内酰胺类给药策略。
- 纳入药物包括美罗培南、头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、头孢地尔、美罗培南/法硼巴坦、亚胺培南/瑞来巴坦和氨曲南。
- 共识开发遵循ACCORD指南,包括多学科专家组、前瞻性注册、证据合成和改良Delphi轮次。
- 体外生命支持技术可引入额外药代动力学改变,可能导致抗生素暴露不足。
- 研究目的为在全国层面概述给药策略和治疗药物监测方案,并基于现有证据制定共识文件。
适用人群与场景
- 重症患者,接受体外生命支持技术(连续性肾脏替代治疗、常规间歇性血液透析、体外膜肺氧合)且感染多重耐药革兰阴性杆菌(MDR-GNB)者。
研究设计与关键结果
- 研究方案分两阶段:I)全国调查;II)共识文件开发。
- 共识文件按ACCORD指南进行,包括:a)建立多学科专家组;b)前瞻性注册共识;c)证据合成;d)改良Delphi轮次。
- 纳入抗菌药物:美罗培南、头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、头孢地尔、美罗培南/法硼巴坦、亚胺培南/瑞来巴坦和氨曲南。
- 体外生命支持技术包括:连续性肾脏替代治疗、常规间歇性血液透析和体外膜肺氧合。
证据类型、等级与局限
- 证据类型:研究方案(全国调查与共识文件开发方案)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
指南或共识出处
- DOSEBL研究方案,发表于Farm Hosp。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Infections caused by multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients present a challenge for timely and appropriate antibiotic treatment. This is particularly important in patients undergoing extracorporeal life-support techniques such as renal replacement therapy and extracorporeal membrane oxygenation. These techniques can introduce additional pharmacokinetic alterations, potentially leading to suboptimal exposure to antibiotics. This study aims to outline dosing strategies and therapeutic drug monitoring protocols for new β-lactam antibiotics effective against MDR-GNB in critically ill patients undergoing extracorporeal life-support techniques at a national level. Additionally, the study seeks to develop a consensus document, based on available evidence.
METHODS: The project will comprise two main phases: I) a national survey and II) the development of a consensus document. This consensus document, undertaken according to ACCORD guidelines, will encompass: a) establishment of a multidisciplinary panel of experts, b) prospective registration of the consensus, c) evidence synthesis, d) modified Delphi rounds. The antimicrobials to be included will be: meropenem, ceftazidime/avibactam, ceftolozane/tazobactam, cefiderocol, meropenem/vaborbactam, imipenem/relebactam, and aztreonam. Extracorporeal life-support techniques will include continuous renal replacement therapy, conventional intermittent hemodialysis, and extracorporeal membrane oxygenation.
DISCUSSION: The availability of extracorporeal life-support techniques has expanded significantly in recent years, alongside a rise in the prevalence of infections caused by MDR-GNB. There is a need to develop evidence-based tools of high quality to standardize dosing and monitoring strategies for new β-lactam antibiotics.
参考来源
- Pau-Parra A, Núñez-Núñez M, Sadyrbaeva-Dolgova S, et al. [Translated article] National survey and consensus document on dosing strategies for beta-lactam antibiotics against multidrug-resistant gram-negative bacilli (MDR-GNB) in critically ill patients undergoing extracorporeal life-support techniques: The DOSEBL study protocol. Farm Hosp. 2024. PMID: 39675936. doi:10.1016/j.farma.2024.11.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。